Trial · NCT02490293
Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?
NCT02490293, Not applicable, Completed, Taeho Hong; results first posted 2017-04-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder? Trials, record NCT02490293. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02490293
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?
- NCT number
- NCT02490293
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 198 participants, actual
- Lead sponsor
- Taeho Hong
- Conditions
- Acute Cholecystitis
- Interventions
- Cephalosporin, Placebo
- First posted
- 2015-07-03
- Last updated
- 2017-04-07
- Results first posted
- 2017-04-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Infectious Postoperative Complications | 30 days | Incidence of infectious postoperative complications in patients who underwent a laparoscopic cholecystectomy due to grade I Tokyo guidelines for acute cholecystitis or grade II Tokyo guidelines for acute cholecystitis except the evidence of gallbladder perforation, with antibiotics or placebo |
| Secondary | Duration of Hospitalization | participants will be followed for the duration of hospital stay, an expected average of 2 days | the duration between the operation day and the day of discharge |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Infectious Postoperative Complications | 30 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Duration of Hospitalization | participants will be followed for the duration of hospital stay, an expected average of 2 days | days | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Infectious Postoperative Complications | Group A (Cephalosporin) | 8 | Participants | ||
| Number of Participants With Infectious Postoperative Complications | Group B (Placebo) | 7 | Participants | ||
| Duration of Hospitalization | Group A (Cephalosporin) | 3.5 | Standard Deviation 1.1 | days | |
| Duration of Hospitalization | Group B (Placebo) | 3.2 | Standard Deviation 1.0 | days |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group A (Cephalosporin) | 96 | |
| Overall Study | STARTED | Group B (Placebo) | 102 | |
| Overall Study | COMPLETED | Group A (Cephalosporin) | 94 | |
| Overall Study | COMPLETED | Group B (Placebo) | 99 | |
| Overall Study | NOT COMPLETED | Group A (Cephalosporin) | 2 | |
| Overall Study | NOT COMPLETED | Group B (Placebo) | 3 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | pancreatitis | Gastrointestinal disorders | Group A (Cephalosporin) | 0 | 93 | |
| other | pancreatitis | Gastrointestinal disorders | Group B (Placebo) | 3 | 95 | |
| other | diarrhea | Gastrointestinal disorders | Group A (Cephalosporin) | 3 | 93 | |
| other | diarrhea | Gastrointestinal disorders | Group B (Placebo) | 1 | 95 | |
| other | CBD stone | Hepatobiliary disorders | Group A (Cephalosporin) | 3 | 93 | |
| other | CBD stone | Hepatobiliary disorders | Group B (Placebo) | 3 | 95 | |
| other | wound infection | Infections and infestations | Group A (Cephalosporin) | 8 | 93 | |
| other | wound infection | Infections and infestations | Group B (Placebo) | 7 | 95 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A (Cephalosporin) | ||
| Total, all-cause mortality | Group B (Placebo) | ||
| Total, other adverse events | Group A (Cephalosporin) | 14 | 93 |
| Total, other adverse events | Group B (Placebo) | 14 | 95 |
| Total, serious adverse events | Group A (Cephalosporin) | 0 | 93 |
| Total, serious adverse events | Group B (Placebo) | 0 | 95 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Group A (Cephalosporin) vs Group B (Placebo): Number of Participants With Infectious Postoperative Complications | Trial comparisons |
| Group A (Cephalosporin) vs Group B (Placebo): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02490293
GET https://conductscience.org/api/trials/v1/NCT02490293/registered